@OncoImmunity

NEC OncoImmunity AS develops bioinformatics software to empower precision cancer immunotherapy, using machine-learning to profile neoantigens from NGS data.

 Oslo, Norway
OncoImmunity.com
Joined January 2016
  • Tweets64
  • Following162
  • Followers212
2Media
Learn more about our collaboration with Nagasaki university in the infectious disease space #ai #drugdiscovery #biopharma #vaccines #globalhealth nec.com/en/press/202308/glob…

Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting...

Nagasaki University and NEC OncoImmunity (NOI), a leading artificial intelligence (AI) company, have announced that they will collaborate to use NOI’s AI platform to design universal vaccines against...

nec.com
140
NEC OncoImmunity AS retweeted
BioWorld
@BioWorld12 Apr 2022
NEC Oncoimmunity bags $4.8M to develop vaccines for SARS-CoV-2 variants, other betacoronaviruses bioworld.com/articles/517803… #biotech #biopharma #biotechnology #BiotechNews #LifeSciencesNews #biopharmaceutical #lifesciences #pharma @CEPIvaccines @OncoImmunity
3
1
NEC OncoImmunity AS retweeted
CEPI
@CEPIvaccines12 Apr 2022
CEPI støtter norske NEC @OncoImmunity som bruker kunstig intelligens i utviklingen av en bredspektret betakoronavaksine @DagensMedisin 🇳🇴 tinyurl.com/2p9ddh6t

Norsk selskap skal utvikle koronavaksine som gir bred beskyttelse, med støtte fra CEPI

Med kunstig intelligens skal norske NEC OncoImmunity finne vaksine-antigener som kan gi bred beskyttelse mot ulike varianter av betakoronavirus. Prosjektet får inntil 42 millioner kroner i CEPI-stø...

dagensmedisin.no
6
6
A major milestone for our team! Congrats to all involved nec.com/en/press/202204/glob…

CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective...

CEPI, the Coalition for Epidemic Preparedness Innovations, and NEC Corporation (NEC: TSE: 6701) today announced the latest funding award under its US$200m programme to advance the development of...

nec.com
1
5
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets: Press Releases | NEC nec.com/en/press/202203/glob…

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate...

nec.com
2
6
businesswire.com/news/home/2…

NEC OncoImmunity Publishes a Unique HLA Typing Technology That Discovers New HLA Alleles, and Tumor...

NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide p...

businesswire.com
1
1
2
We are hiring! Looking for talented people to use their data science and software skills in the fight against cancer and infectious diseases. finn.no/job/employer/company…

Et blikk på innsiden av NEC ONCOIMMUNITY AS

NEC OncoImmunity is a machine-learning based company providing software to empower personalized cancer immunotherapy, and infectious disease.

finn.no
2
2
Exciting to see our AI approach to develop universal blueprints for vaccine design now published in the peer review journal Scientific Reports nature.com/articles/s41598-0…
1
2
An artificial intelligence T-cell diagnostic test for COVID-19 businesswire.com/news/home/2…

NEC OncoImmunity AS and Oslo University Hospital Team Up to Develop a Diagnostic for COVID-19 Using...

NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awa...

businesswire.com
2
3
NEC’s AI-driven Blueprint for a Safe, Universally Effective New Coronavirus Vaccine: Business Insights | NEC nec.com/en/global/insights/a…
1
1
4
@OncoImmunity is recruiting a Quality Assurance Manager - Join our team and help build quality #ai software to combat cancer and infectious disease: finn.no/job/management/ad.ht…
2
@OncoImmunity is recruiting a Quality Assurance Manager - Join our team and help build quality #ai software to combat cancer and infectious disease: linkedin.com/jobs/view/18986…
2
2
Congratulations to the team for their hard work in adapting the NEC Immune Profiler technology to help in the fight against COVID-19 #AI #COVID19vaccine business.financialpost.com/p…

NEC Publishes Design Blueprints for SARS-CoV-2 Vaccines Using Its Artificial Intelligence Technology

financialpost.com
2
1
4
Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2: toward universal blueprints for vaccine designs biorxiv.org/content/10.1101/…

Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2: toward universal bluepr...

The global population is at present suffering from a pandemic of Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The...

biorxiv.org
3
9
NEC OncoImmunity AS retweeted
Startuplab@startuplabno29 Jul 2019
It's been a pleasure to work with Richard, @Trevor_Clancy, @andtuv and the rest of the team, and we're very proud to have been part of this journey! Further, we are excited about the opportunities that lie ahead, and look forward to seeing what OncoImmunity going forward!
2
9
NEC OncoImmunity AS retweeted
Startuplab@startuplabno29 Jul 2019
Huge congrats to our portfolio company @OncoImmunity - now acquired by @NEC_corp. A great merger that increases OncoImmunity’s reach, ensuring that their machine learning software improves cancer treatments for as many people as possible! nec.com/en/press/201907/glob…

NEC acquires Norwegian bioinformatics company, OncoImmunity AS

NEC Corporation (NEC; TSE: 6701) today announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight...

nec.com
6
10
2
30
NEC OncoImmunity AS retweeted
MalmbergLab@MalmbergLab8 May 2019
scRNA-seq reveals heterogeneity in the CD56bright NK cell subset and nondramatic transitioning into CD56dim NK cells @Trevor_Clancy @AlinePfefferle and Herman Netskar biorxiv.org/content/10.1101/…
2
11
2
28
NEC OncoImmunity AS retweeted
Trevor Clancy@Trevor_Clancy24 Apr 2019
OncoImmunity was pleased to present exciting results on improved neoantigen presentation and immunogenicity at the #NeoAg Summit today lnkd.in/eVkqvmz

#neoag | Trevor Clancy

OncoImmunity was pleased to present exciting results on improved neoantigen presentation and immunogenicity at the #NeoAg Summit today

linkedin.com
1
3
12
NEC OncoImmunity AS retweeted
EIC Norway@eic_norway12 Apr 2019
Gode nyheter rett før påskeferien: @IselinNybo @Kunnskapsdep har gitt beskjed til EU om at Norge vil delta i #HorisontEuropa 👏 Med økt budsjett og større fokus på skalering av bedrifter lover dette godt for norsk næringsliv! #EIC @InnovasjonNorge uniforum.uio.no/nyheter/2019…
4
14
NEC OncoImmunity AS retweeted
Jutta Heix@heix_jh14 Mar 2019
"We believe that OncoImmunity's Immuneoprofiler™ software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens." said Reid Rubsamen, CEO of Flow Pharma. Congratulations to the dedicated OncoImmunity team!
NEC OncoImmunity AS@OncoImmunity12 Mar 2019
Looking forward to start an exciting neoantigen project with Flow Pharma and their powerful vaccine technology #neoantigen #personalizedmedicine businesswire.com/news/home/2… …
2
10
Load more